This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases fourth-quarter 2020 results on Feb 4.
Will Merck (MRK) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
J&J's (JNJ) Coronavirus Vaccine Shows 66% Efficacy in Phase III
by Zacks Equity Research
J&J's (JNJ) phase III ENSEMBLE study on its single-dose COVID-19 vaccine candidate meets all primary and key secondary endpoints.
Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.
Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.
The Zacks Analyst Blog Highlights: NVIDIA, Verizon, AstraZeneca, Micron Technology and Anthem
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Verizon, AstraZeneca, Micron Technology and Anthem
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $52.04, marking a -0.12% move from the previous day.
Top Stock Reports for NVIDIA, Verizon & AstraZeneca
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA (NVDA), Verizon (VZ), and AstraZeneca (AZN).
Regeneron (REGN) Reports Positive Data on Cocktail for COVID-19
by Zacks Equity Research
Regeneron (REGN) reports positive initial results from a phase III study evaluating REGEN-COV antibody cocktail as a passive vaccine for the prevention of people at high risk of COVID-19 infection.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $54.44, moving +0.8% from the previous trading session.
Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer
by Zacks Equity Research
The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.
How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?
by Zacks Equity Research
Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?
Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX
by Zacks Equity Research
Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
by Zacks Equity Research
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.
Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal
by Kinjel Shah
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.
AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $52.24, moving -0.63% from the previous trading session.
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up
by Zacks Equity Research
Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug
by Zacks Equity Research
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Top Analyst Reports for Visa, T-Mobile & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), T-Mobile US (TMUS), and Union Pacific (UNP).
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine
by Zacks Equity Research
Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing
by Zacks Equity Research
AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.
Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris
by Zacks Equity Research
Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.